A new concept to stimulate mucosal as well as systemic immunity by parenteral vaccination as applied to the development of a live attenuated<i>Salmonella enterica</i>serovar Dublin vaccine

Mizuno, T.; Ploeg, Richard; Trott, Darren J.

doi:10.1051/vetres:2007031

Cited by 8 publications

(9 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The strain distribution analysis demonstrated that the bacteria had completely vanished from mouse organs at 14 days after vaccine immunization. These findings are consistent with a previous report (Mizuno et al ., ) in which that the vaccination strain was isolated from the heart, blood, liver and spleen of mice at 1 day after immunization and was eliminated at the end of the study. The results also showed that the inhibin gene vaccine had no effect on organ weights or histopathological changes.…”

Section: Discussionmentioning

confidence: 99%

The efficacy, biodistribution and safety of an inhibinDNAvaccine delivered by attenuatedSalmonella choleraesuis

Chen

Li²,

Xue

et al. 2017

Microbial Biotechnology

View full text Add to dashboard Cite

Summary DNA vaccines, the third‐generation vaccines, were extensively studied. The attenuated Salmonella choleraesuis (S. choleraesuis) was widely focused as a carrier to deliver DNA vaccines in the chromosome–plasmid balanced‐lethal system. The efficacy of inhibin DNA vaccine delivered by attenuated S. choleraesuis was proved in mice and cows in our previous studies. In this study, the efficacy of inhibin DNA vaccine was confirmed in rhesus monkeys. To further study the biodistribution and safety, the mice were immunized under laboratory conditions. The results of the rhesus monkeys showed the plasma IgA and IgG titres against inhibin were elevated, and the oestradiol (E2) and progesterone (P4) levels were increased with immunizing inhibin DNA vaccine. The biodistribution and safety assessment displayed the body weight, pathological change and haematology indexes where there is no significant difference between vaccinated mice and control. And the genomics analysis showed there was no integration of the inhibin gene into the mouse genome 2 months after immunization. This study indicated the inhibin DNA vaccine delivered by attenuated S. choleraesuis was safe. And this vaccine was a potential means to improve their reproductive traits in primates and other animals.

show abstract

Section: Discussionmentioning

confidence: 99%

The efficacy, biodistribution and safety of an inhibinDNAvaccine delivered by attenuatedSalmonella choleraesuis

Chen

Li²,

Xue

et al. 2017

Microbial Biotechnology

View full text Add to dashboard Cite

show abstract

“…N-RM25 was confirmed to be highly stable with no cross-resistance to ten different antimicrobials. Following parenteral vaccination of mice, N-RM25 was also confirmed to be safe and efficacious, inducing both significant serum and mucosal immune responses and protecting against homologous lethal challenge infection [27].…”

Section: Introductionmentioning

confidence: 92%

“…These results suggest that some factors, possibly mucosal immunity, contribute to the development of inflammatory reactions at the site. It was previously shown in a trial using mice that N-RM25 administered via the parenteral route induced significant mucosal immune responses in the gut 14 days post vaccination [27].…”

Section: Groupmentioning

confidence: 99%

“…The vaccine strain used in this study, N-RM25, was created from S. Dublin wild strain FD436 utilising metabolic-drift mutations [27]. FD436 was also used as the challenge strain in the homologous vaccine trial.…”

Section: Bacterial Preparationmentioning

confidence: 99%

“…A new, live attenuated vaccine, N-RM25, was previously created from a virulent wild strain of S. Dublin utilising metabolicdrift (spontaneous chromosomal) mutations induced by nalidixic acid and rifampicin followed by selection using new criteria developed based on a new immunity stimulation concept of slow "drip feeding" [27]. N-RM25 was confirmed to be highly stable with no cross-resistance to ten different antimicrobials.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Intramuscular vaccination of young calves with aSalmonellaDublin metabolic-drift mutant provides superior protection to oral delivery

2008

Self Cite

View full text Add to dashboard Cite

-In homologous and heterologous challenge trials using calves ≤ 6 weeks old, this comparative study investigated safety, in vivo behaviour and protective properties of oral and intramuscular vaccination with recently developed live attenuated Salmonella Dublin mutant N-RM25. Neither oral nor intramuscular vaccination produced unacceptable side effects. However, the vaccine strain was isolated for up to eight days from the faeces of orally vaccinated calves, but not intramuscularly vaccinated calves. Irrespective of the vaccination route, N-RM25 was isolated in low numbers (≤ 1 × 10 2 cfu/g) from the liver and spleen of calves euthanized at different time points post-vaccination. Vaccination by either route significantly reduced clinical signs and faecal shedding, prevented the development of systemic infection and protected calves from homologous lethal challenge conducted within 14 days post-immunisation. No challenge strain was isolated from major organs and the gut at 18 days post-challenge (except for a single mesenteric lymph node (MLN) specimen from the intramuscular group, but only following enrichment). Following heterologous challenge with a virulent Salmonella Typhimurium strain at 14 and 20 days post-immunisation, all vaccinated animals exhibited significantly fewer clinical signs and colonisation of the intestinal tract than non-vaccinated controls. When compared to oral vaccination, intramuscular vaccination significantly reduced the frequency of faecal shedding of S. Typhimurium (p = 0.0023) and markedly reduced colonisation of MLN. The findings indicate that intramuscular administration of N-RM25 was safer in terms of environmental contamination by the vaccine and provided better early onset protection in young calves following both homologous and heterologous challenge.Salmonella Dublin / metabolic-drift mutant / live attenuated vaccine / early onset protection / calf

show abstract

Development of Salmonella Enteritidis vaccine candidate based on streptomycin independent suppressor and metabolic drift rifampicin resistance-attenuating markers

Shehata

Tarabees

El-Sayed

et al. 2020

Heliyon

View full text Add to dashboard Cite

Salmonella is one of the most frequent food-borne pathogens and remains public health threat globally. The control of Salmonella in poultry, the main reservoir of non-typhoidal salmonellae, is a fundamental approach to ensure the safety of poultry products for human consumption. In the present study, a new live attenuated Salmonella enterica serovar Enteritidis vaccine candidate containing three attenuating markers based on streptomycin-independent (Sm-id) suppressor, and metabolic drift antibiotic resistance (MD- “res”) was developed. The streptomycin dependent (Smd) mutants were derived from Salmonella Enteritidis wild-type strain using streptomycin. Then the Sm-id mutants were derived from the isolated Smd mutants and designated “Smd→Sm-id”. A third MD- “res” marker was generated from Smd→Sm-id using rifampicin (Rif) and designated “Smd→Sm-id→Rif”. The colony sizes of these mutants were stable after more than 50 serial passages on blood agar; reversion to virulence can be almost excluded. The safety and efficacy of Smd→Sm-id and Smd→Sm-id→Rif were evaluated in one-day-old commercial layer chicks. Both mutants proved to be safe in terms of clinical signs, mortalities, lesion scores of visceral organs and rapid clearance when administered orally at a dose of 10 8 colony forming unit (CFU), whereas birds inoculated with 10 8 CFU Salmonella Enteritidis wild-type strain showed diarrhea, mortalities (3/40) and necrosis in liver and spleen. Chickens vaccinated with the developed mutants showed no seroconversion; however, wild-type strain induced a significant seroconversion at 3-week-postvaccination (wpv). The developed mutants protected chickens against challenge with 10 8 CFU of Salmonella Enteritidis wild-type strain at 3-wpv. Vaccinated birds showed neither clinical signs nor mortalities during two-week post-challenge. In addition, the challenge strain could not be detected in pooled liver and spleen samples (0/5) at 7 th day post-inoculation (dpi). However, non-vaccinated challenged birds showed diarrhea and the challenge strain was re-isolated from pooled liver and spleen samples (3/5) at 7 th dpi. In conclusion, the developed mutants are safe and fully protected immunized chickens following heterologous challenge. It is obvious that the genetic characterization of these mutants and evaluation of different vaccination regimes are still in demand.

show abstract

A new concept to stimulate mucosal as well as systemic immunity by parenteral vaccination as applied to the development of a live attenuatedSalmonella entericaserovar Dublin vaccine

Cited by 8 publications

References 31 publications

The efficacy, biodistribution and safety of an inhibinDNAvaccine delivered by attenuatedSalmonella choleraesuis

The efficacy, biodistribution and safety of an inhibinDNAvaccine delivered by attenuatedSalmonella choleraesuis

Intramuscular vaccination of young calves with aSalmonellaDublin metabolic-drift mutant provides superior protection to oral delivery

Development of Salmonella Enteritidis vaccine candidate based on streptomycin independent suppressor and metabolic drift rifampicin resistance-attenuating markers

Contact Info

Product

Resources

About